Clinical Trial Update: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab in patients undergoing donor peripheral blood stem cell transplantation for relapsed or refractory B-cell lymphomas; complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Lymphoblastic Leukemia
• Burkitt Lymphoma
• Chronic Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia Refractory
• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone Lymphoma
• Follicular Lymphoma
• Hairy Cell Leukemia
• Hodgkin Lymphoma
• Hodgkin Lymphoma Recurrent Refractory
• Immunoblastic Large Cell Lymphoma
• Intraocular Lymphoma
• Lymphoblastic Leukemia
• Lymphoblastic Lymphoma
• Lymphoplasmacytic Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone B-cell Lymphoma
• Mucosa-associated Lymphoid Tissue Lymphoma
• Non-hodgkin Lymphoma
• Post-transplant Lymphoproliferative Disorder
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2017-05-22